| --- | --- | --- | --- | --- | --- | --- | |-----------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | Corporate Overview NASDAQ: STTK April 1, 2021 | | | | | | | | | | | | | | | SHATTUCK PIONEERING NOVEL BI-FUNCTIONAL FUSION PROTEINS EXPANDING THE BOUNDARIES OF BIOLOGIC MEDICINES Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substan ...

| --- | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------|-------| | | | | | | | Corporate Overview NASDAQ: STTK March 16, 2021 | | | | | | | | | | | SHATT PIONEERING NOVEL BI-FUNCTIONAL FUSION PROTEINS EXPANDING THE BOUNDARIES OF BIOLOGIC MEDICINES Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are base ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or orga ...

| --- | --- | --- | --- | --- | |-------------------------------------------------|-------|-------|-------|-------| | | | | | | | Corporate Overview NASDAQ: STTK January 8, 2021 | | | | | | | | | | | SHATTUCK PIONEERING NOVEL BI-FUNCTIONAL FUSION PROTEINS EXPANDING THE BOUNDARIES OF BIOLOGIC MEDICINES Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...